PolyPid(PYPD)
Search documents
PolyPid(PYPD) - 2024 Q2 - Earnings Call Transcript
2024-08-14 17:25
PolyPid Ltd (NASDAQ:PYPD) Q2 2024 Results Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, US Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Securities Raghuram Selvaraju - H.C. Wainwright & Co. Operator Greetings and welcome to the PolyPid Second Quarter 2024 Conference Call. At this time, partic ...
PolyPid(PYPD) - 2024 Q1 - Quarterly Report
2024-08-14 11:47
Exhibit 99.1 POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page | --- | --- | |-------------------------------------------------------------------------------------------|------------| | | | | Interim Condensed Consolidated Balance Sheets | 1 - 2 | | | | | Interim Condensed Consolidated Statements of Operations | 3 | | | | | Interim Condensed Consolidated Statements of Shareholders' Equity (Deficit) | 4 - 6 ...
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
Newsfilter· 2024-08-02 00:31
Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Expected in Fourth Quarter of 2024; Top-Line Results Anticipated in First Quarter of 2025 P ...
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
GlobeNewswire News Room· 2024-08-02 00:31
Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Expected in Fourth Quarter of 2024; Top-Line Results Anticipated in First Quarter of 2025 P ...
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
Newsfilter· 2024-06-18 11:00
Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs PETACH TIKVA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections (SSIs). The Company also provided an update on its ongoing SHIELD II Phase 3 trial for ...
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial
Newsfilter· 2024-06-10 11:00
The event will feature Charles E. Edmiston, Ph.D. (Emeritus Professor of Surgery, Division of Vascular Surgery, Medical College of Wisconsin), who will discuss the significant clinical and economic burden, and current medical practice, for the prevention of surgical site infections (SSIs). It will also highlight PolyPid's lead product candidate, D-PLEX100, and its ongoing Phase 3 SHIELD II trial evaluating D-PLEX100 for the prevention of abdominal colorectal SSIs. PolyPid management intends to provide an up ...
PolyPid(PYPD) - 2024 Q1 - Earnings Call Transcript
2024-05-10 02:38
PolyPid Ltd (NASDAQ:PYPD) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - IR Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, US Conference Call Participants Roy Buchanan - JMP Operator Thank you all for participating in PolyPid's First Quarter 2024 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulaw ...
PolyPid(PYPD) - 2023 Q4 - Annual Report
2024-03-06 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...
PolyPid(PYPD) - 2023 Q4 - Earnings Call Transcript
2024-02-14 16:13
PolyPid Ltd (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 8:30 AM ET Company Participants Brian Ritchie - IR Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Boobalan Pachaiyappan - HC Wainwright Operator Greeting morning and welcome to the PolyPid Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. And I ...
PolyPid(PYPD) - 2023 Q3 - Earnings Call Transcript
2023-11-12 06:08
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET In fact, as we said would be the case by this time, we currently have approximately 20 centers open, the majority of which are outside of Israel. The vast majority of these 20 centers have opened only in the last few weeks. Therefore, while we currently have approximately 50 patients recruited into the SHIELD II trial, we expect enrollment to ramp up shortly. To this end, we anticipate having approximately 40 centers op ...